Emcure Pharma shares will be in focus during the trading session on Friday as Bain Capital-affiliated entity BC Investments IV is expected to sell a 2.4% stake in the company for Rs 551 crore today in a block deal, according to media reports citing sources familiar with the matter.
Key Highlights
- Bain-backed BC Investments IV plans block deal to offload 2.4% Emcure stake for ₹551 crore.
- Transaction covers 45.5 lakh shares at ~₹1,279.80 each, led by Kotak Securities as manager.
The floor price for the 45.5 lakh share transaction has been set at Rs 1,279.80 per share, which is a slight discount to its previous close of Rs 1,280.30. Kotak Securities will serve as the issue's lead manager. As of March 2025, BC Investments IV owned 8.68 percent of Emcure.
Emcure Pharmaceuticals reported a 63% increase in consolidated net profit year on year (YoY) to Rs 197 crore in the March quarter. The Pune-based drugmaker reported a 19.5 percent YoY increase in revenue from operations to Rs 2,116 crore. The company performed well in both its domestic and international businesses.
Emcure Pharma's shares have recently underperformed. The stock is down 4% in the last month and nearly 13% year to date. The stock has dropped nearly 19% from its all-time high of Rs 1,580, set in September 2024.
Also Read: Torrent Pharma to Acquire 46.39% Stake in JB Chemicals for Rs 25,689 Cr
Established in Pune in 1981, Emcure Pharmaceuticals is an Indian pharmaceutical company that creates, produces, and distributes a wide variety of pharmaceutical products in several important therapeutic areas. It is the leading pharmaceutical company in gynaecology and HIV antiviral therapeutics for the MAT September 2023.
